The autoimmune disease and cancer drug developer plans to float in Hong Kong having recently secured $160m from investors including a Charoen Pokphand-backed fund.
Genor Biopharma, a China-based immuno-oncology therapy developer backed by poultry feed producer Charoen Pokphand, has filed to raise up to HK$2.48bn ($320m) in an initial public offering, DealStreetAsia reported yesterday.
Founded in 2007, Genor is developing monoclonal antibodies to treat cancers including solid tumours and blood cancers, in addition to autoimmune diseases such as rheumatoid arthritis.
The company has 15 drug candidates in its pipeline and is overseeing 18 clinical trials in Asia at present, according to DealStreetAsia.
The IPO…
